Ascendis Pharma AS

Stock Chart, Company Information, and Scan Results

$196.64(as of Sep 22, 3:58 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ascendis Pharma AS Company Information, Fundamentals, and Technical Indicators

Stock Price$196.64
Ticker SymbolASND
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees1,017
CountyUSA
Market Cap$11,970.4M
EBIDTA-248.6M
10-Day Moving Average197.95
P/E Ratio-46.30
20-Day Moving Average197.81
Forward P/E Ratio43.29
50-Day Moving Average187.74
Earnings per Share-5.36
200-Day Moving Average160.74
Profit Margin-24.58%
RSI52.05
Shares Outstanding60.6M
ATR6.37
52-Week High208.16
Volume1,061,775
52-Week Low118.03
Most Recent Support Level193.00
Book Value-187.6M
Most Recent Resistance Level200.50
P/B Ratio-66.93
Upper Keltner212.15
P/S Ratio25.58
Lower Keltner183.47
Debt-to-Equity Ratio212.15
Next Earnings Date11/06/2025
Cash Surplus-441.0M
Next Ex-Dividend DateUnknown

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Ascendis Pharma AS In Our Stock Scanner

As of Sep 23, 2025
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.